三联疗法新选择：氟替美维吸入粉雾剂(Trelegy Ellipta)获准用于特定慢阻肺与哮喘患者

Flutimavir inhalation powder (TrelegyEllipta) is used for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and asthma.

What diseases does flutimavir inhalation powder (Trelegy Ellipta) treat?

It is suitable for maintenance treatment of the following diseases:

1. Chronic obstructive pulmonary disease (COPD): including chronic bronchitis and/or emphysema.

2. Asthma: Applicable to adults aged 18 and above.

Restricted Use: Not indicated for the relief of acute bronchospasm.

The pictures are from public channels (such as the official website of the FDA, the official website of the original drug manufacturer, etc.) and are for reference only.

Usage and dosage of flutimavir inhalation powder (Trelegy Ellipta)

1. Route of administration

Oral inhalation only.

2. Medication frequency

Once a day, one puff each time.

3. Medication time

It should be used at a fixed time every day and not more than once in 24 hours.

4. Recommended dosage for maintenance treatment of chronic obstructive pulmonary disease

The recommended dosage is flutimavir inhalation powder spray 100/62.5/25mcg, once a day.

If dyspnea occurs between doses, an inhaled short-acting β₂-agonist (such as albuterol) should be used for relief.

5. Recommended dose for asthma maintenance treatment

The starting dose can be flutimavir inhalation powder spray 100/62.5/25mcg or 200/62.5/25mcg, once a day.

Dose selection should be based on the severity of the patient's disease, previous asthma treatment (e.g., dose of inhaled corticosteroids), current symptom control, and risk of future exacerbations.

6. Post-medication treatment

Rinse your mouth with water after inhalation and do not swallow to reduce the risk of candida infection in the oropharynx.

7. Dose adjustment for special groups

Elderly patients, patients with renal impairment or patients with moderate liver impairment do not need to adjust the dose.

Contraindications of Flutimavir Inhalation Powder Aerosol (Trelegy Ellipta)

1. Those with a history of severe allergy to fluticasone furoate, umeclidinium bromide, vilanterol or any excipients (including milk protein).

2. For the treatment of status asthmaticus or other acute chronic obstructive pulmonary disease or asthma attacks that require intensive treatment.

Side effects of flutimavir inhalation powder (Trelegy Ellipta)

1. Common adverse reactions in patients with chronic obstructive pulmonary disease (incidence ≥1%)

Upper respiratory tract infection, pneumonia, bronchitis, oral candida infection, headache, back pain, joint pain, influenza, sinusitis, pharyngitis, rhinitis, dysgeusia, constipation, urinary tract infection, diarrhea, gastroenteritis, oropharyngeal pain, cough, dysphonia.

2. Common adverse reactions in patients with asthma (incidence ≥2%)

Pharyngitis/nasopharyngitis, upper respiratory tract infection/viral upper respiratory tract infection, bronchitis, respiratory tract infection/viral respiratory tract infection, sinusitis/acute sinusitis, urinary tract infection, rhinitis, influenza, headache, back pain.

3. Serious adverse reactions

Pneumonia, oral candida infection, immunosuppression, adrenal insufficiency, paradoxical bronchospasm, cardiovascular effects, reduced bone density, glaucoma and cataracts, worsening of urinary retention, etc.